3631 results for «767»
3631 results
When less is better - Differentiated therapies to safely achieve TR 0-1+
19 May 2026 – From EuroPCR 2026
Therapeutic goals in tricuspid regurgitation are evolving, with increasing emphasis on achieving near-complete elimination of regurgitation (TR 0–1+) through differentiated transcatheter strategies.
This EuroPCR 2026 session explores how transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) can be used in a complementary way to reach...
Renal denervation 360°: are you ready for the future?
20 May 2026 – From EuroPCR 2026
Where does renal denervation (RDN) stand today, and where is it heading next?
This EuroPCR 2026 session provides a comprehensive update on RDN, covering its safe and effective use in line with the latest European recommendations. Faculty members share practical guidance on patient selection, programme implementation, and...
The right therapy for right heart failure and tricuspid regurgitation: fixing my patient congestion, not just a valve
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session shifts the focus in tricuspid regurgitation from anatomy alone to the broader context of right heart failure and systemic congestion. It highlights the limitations of purely leaflet-based strategies, particularly in advanced disease and in the presence of severe right ventricular dysfunction.
The discussion...
Aortic regurgitation in 2026
21 May 2026 – From EuroPCR 2026
Get a comprehensive overview of contemporary management strategies for aortic regurgitation, a condition that remains frequently underdiagnosed and undertreated despite significant advances in transcatheter therapies thanks to this EuroPCR 2026 session.
The programme reviews current diagnostic and treatment pathways, including guideline-based management and the role of surgical...
LDL-C management: should it begin in the cathlab?
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session examines the evolving role of LDL cholesterol management in patients undergoing percutaneous coronary intervention (PCI), with a focus on the potential benefits of initiating intensive lipid-lowering strategies early in the patient pathway.
The discussion reviews emerging evidence on PCSK9 inhibition in elective PCI...
Innovation in action: achieving optimal outcomes in mitral regurgitation
20 May 2026 – From EuroPCR 2026
A growing mitral valve portfolio is reshaping how mitral regurgitation is treated, offering tailored solutions across a broader range of patient anatomies and clinical scenarios.
This EuroPCR 2026 session focuses on innovations in transcatheter mitral therapies, highlighting how mitral transcatheter edge-to-edge repair (TEER) with the PASCAL Precision...
Active unloading with Impella heart pumps in elective and emergent patients
21 May 2026 – From EuroPCR 2026
This session presents the latest evidence on the use of microaxial Impella heart pumps in both elective high-risk and emergent cardiogenic shock patients. It highlights the importance of organised systems of care in improving survival outcomes and explores current data and expert consensus on mechanical circulatory...
Ascending into the future with drug-coated balloons
21 May 2026 – From EuroPCR 2026
Step into the future of interventional cardiology with comprehensive insights into drug‑coated balloons (DCB). This session covers the new DCB ARC guidelines, previews findings from the impactful BASKET BALL randomised trial, and examines real-world evidence from the SCORE registry. It also addresses the optimisation of acute...
IVUS and NIRS imaging: a pathway to improve outcomes in stable and acute coronary syndromes
19 May 2026 – From EuroPCR 2026
IVUS-guided PCI is well established in complex coronary interventions, but combining it with near-infrared spectroscopy (NIRS) is opening a new dimension by linking vessel geometry with plaque biology.
This EuroPCR 2026session explores how IVUS-NIRS imaging improves PCI planning and risk stratification in both stable and acute coronary...
Lessons learned to pave the way for future-proof strategies in TAVI
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session focuses on how current experience in transcatheter aortic valve implantation (TAVI) can be translated into more durable strategies for the future, particularly in patients with bicuspid aortic valve disease.
It provides a comprehensive overview of anatomical, clinical, and procedural considerations in this challenging...
Artificial intelligence-powered precision: CT-guided PCI and the future of image-guided therapy
19 May 2026 – From EuroPCR 2026
Image-guided PCI is entering a new era, driven by artificial intelligence and advanced CT technologies that are reshaping how coronary interventions are planned and performed.
This EuroPCR 2026 session explores the integration of photon-counting CT into PCI workflows, highlighting its improved spatial resolution, enhanced plaque characterisation and...
Advancing mitral care with the Intrepid TMVR system
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the Intrepid transcatheter mitral valve replacement (TMVR) system and its role in expanding treatment options for patients with mitral regurgitation, including complex anatomies such as mitral annular calcification (MAC).
It highlights how the system’s design features and procedural imaging support a streamlined...
DCB: does coating morphology matter for distal embolisation and clinical outcomes?
20 May 2026 – From EuroPCR 2026
Drug-coated balloon (DCB) therapy continues to evolve, with increasing attention on how coating design may influence drug transfer, vessel response and downstream clinical outcomes.
This EuroPCR 2026 session examines the role of coating morphology, comparing amorphous and crystalline technologies and their implications for drug delivery efficiency and...
Mastering complex TAVI: achieving optimal outcomes with Evolut FX+
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session focuses on advancing the management of complex transcatheter aortic valve implantation (TAVI) procedures using Evolut FX+ technology.
It highlights the benefits of supra-annular TAVI in patients with severe bicuspid aortic stenosis, supported by a review of available clinical evidence.
Through a series of case-based...
IBERIS: the first radial renal denervation (RDN) system for the treatment of uncontrolled hypertension
20 May 2026 – From EuroPCR 2026
This session introduces the IBERIS system, the first radial-access platform for renal denervation in patients with uncontrolled hypertension. It covers patient selection, procedural planning, and key technical considerations for both transfemoral and transradial approaches. A LIVE case demonstration highlights essential procedural steps while addressing the clinical...
MagicTouch sirolimus-coated balloon for coronary artery disease and peripheral artery disease treatment: where evidence meets experience
20 May 2026 – From EuroPCR 2026
This session examines the clinical evidence and experiential insights regarding the MagicTouch sirolimus-coated balloon (SCB) for treating coronary and peripheral artery disease. It reviews long-term comparative data versus paclitaxel-coated balloons, application techniques, integration into current practices, and findings from major trials such as SIRONA and SIMPLE-DM,...
Is durability still a topic of concern for TAVI patients? What are the remaining challenges that we need to overcome?
20 May 2026 – From EuroPCR 2026
Examine the clinical relevance of TAVI valve durability and its impact on long-term patient management in aortic stenosis. Review key factors influencing valve performance over time, with a focus on procedural and anatomical determinants of optimal outcomes.
Current concepts and techniques aimed at achieving ideal valve expansion...
Angiography-based physiology: time to change your routine clinical practice?
20 May 2026 – From EuroPCR 2026
This session offers a critical appraisal of angiography-based physiology, with a focus on virtual fractional flow reserve (vFFR) technology. It reviews the latest clinical evidence, including insights from the FAST study programme and the FAST III randomised controlled trial. Gain a clear understanding of current guideline...
Beyond visualisation: the value and future of 4D intracardiac echocardiography in tricuspid repair and replacement
20 May 2026 – From EuroPCR 2026
Explore the transformative role of 4D intracardiac echocardiography in guiding tricuspid edge-to-edge repair (TEER) and valve replacement for tricuspid regurgitation. This session highlights how real-time, high-resolution imaging enhances procedural efficiency and safety, reducing reliance on general anesthesia and shortening procedure times compared to traditional imaging modalities.
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
